PROGRAM CHAIR
Mehdi Hamadani, MD
Professor and Chief of Hematologic Malignancies
Cancer Center Scholar Endowed Chair
Medical College of Wisconsin
Milwaukee, WI
FACULTY PRESENTERS
Farrukh T. Awan, MD, MS, MBA
Professor of Internal Medicine
Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapies
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas
Joseph McGuirk, DO
Schutte-Speas Professor of Hematology-Oncology
Division Director, Hematologic Malignancies and Cellular Therapeutics
Medical Director, Blood and Marrow Transplant
The University of Kansas Cancer Center
Kansas City, Kansas
PROGRAM OVERVIEW
This online interactive educational activity aims to provide hematologists/oncologists and the broader multidisciplinary oncology team with the latest insights into the evolving treatment landscape of chimeric antigen receptor T-cell therapy (CAR-T) for relapsed/refractory (R/R) B-cell lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma. Expert-led discussions will focus on patient selection and referral pathways from community oncology practices to authorized CAR-T centers, collaborative care models between community and academic institutions, and the management of bridging therapy and CAR-T-related toxicities. Dynamic animations will visually illustrate referral processes and care coordination before and after CAR-T infusion. Participants will gain actionable insights to optimize patient outcomes through enhanced treatment selection, care coordination, and post-infusion management.
TARGET AUDIENCE
This activity is designed to meet the educational needs of clinicians involved in the evaluation and management of patients with B-cell non-Hodgkin lymphomas (B-NHLs). Target participants include, but are not limited to, community-based hematologists, hematologist-oncologists, oncologists, oncology nurses, and advanced practice providers, such as nurse practitioners and physician assistants.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Identify referral pathways and strategies for treatment coordination between community-based practice and authorized CAR-T treatment centers
- Describe patient candidates for CAR-T therapy and strategies for CAR-T therapy selection based on benefit-risk profiles and clinical features
- Summarize key considerations and potential strategies for managing toxicities, bridging therapy and post-infusion surveillance for patients eligible for CAR-T therapy
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Mehdi Hamadani, MD | Consulting Fees: Genmab, CRISPR, AlloVir, Caribou Biosciences, Autolus, Forte Biosciences, Byondis, Kite Pharma, and Daiichi Sankyo Speakers Bureau: AstraZeneca, ADC Therapeutics America, BeiGene, Kite Pharma, and Sobi Contracted Research: ADC Therapeutics America, Spectrum Pharmaceuticals, and Astellas Pharma |
| Farrukh T. Awan, MD | Contracted Research: AbbVie/Pharmacyclics Fees for Non-CME/CE Services Received Directly from a Commercial Interest or its Agent: DSMC for Ascentage, AstraZeneca, Caribou Biosciences Consulting Fee: AbbVie, Adaptive Biotechnologies, AstraZeneca, Beigene, Bristol-Myers Squibb, DAVA Oncology, Genmab, Incyte, Invivyd, Loxo Oncology, Miltenyi Biotec, Pierre Fabre |
| Joseph McGuirk, DO | Consulting Fee: Kite Pharma, Caribou Biosciences, Autolus, Bristol-Myers Squibb |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Lauren Scott, MS, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Coordinator, has nothing to disclose.
- Arpan Patel, MD, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Jessica McMullen, MPH, Program Director for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: October 01, 2025
EXPIRATION DATE: October 01, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
